About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

SymBio Pharmaceuticals Limited(4582) Summary

4582
TSE Growth
SymBio Pharmaceuticals Limited
150
JPY
-4
(-2.60%)
Apr 16, 2:56 pm JST
1.05
USD
Apr 16, 1:56 am EDT
Result
PTS
outside of trading hours
149.8
Apr 16, 2:55 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.85
Yield
ー%
Margin Trading Ratio
11,263.25
Stock Price
Apr 16, 2025
Opening Apr 16, 9:00 am
153 JPY 1.06 USD
Previous Close Apr 15
154 JPY 1.07 USD
High Apr 16, 9:05 am
154 JPY 1.07 USD
Low Apr 16, 2:24 pm
149 JPY 1.04 USD
Volume
212,600
Trading Value
0.03B JPY 0.23M USD
VWAP
151.29 JPY 1.06 USD
Minimum Trading Value
15,000 JPY 105 USD
Market Cap
7.19B JPY 0.05B USD
Number of Trades
246
Liquidity & Number of Trades
As of Apr 16, 2025
Liquidity
High
1-Year Average
1,090
1-Year High Jul 19, 2024
25,491
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 11, 2025 0 2,539,100
Apr 4, 2025 0 3,171,900
Mar 28, 2025 0 3,325,800
Mar 21, 2025 0 3,263,000
Mar 14, 2025 0 3,407,200
Company Profile
SymBio Pharmaceuticals Limited specializes in three areas: cancer, hematology, and pain management. The company also commercializes new drug candidates from other companies.
Sector
Pharmaceuticals
SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on rare diseases, primarily in the fields of oncology, hematology, and viral infections. The company advances the development of compounds that have already established proof of concept in humans. Utilizing its unique discovery network and evaluation expertise, SymBio conducts initial screenings through its in-house specialist staff, followed by rigorous evaluations from experienced external experts before finalizing potential in-licensing candidates. By adopting a "labo-less fab-less" strategy to minimize fixed costs, the company concentrates on high-value-added activities while outsourcing routine development tasks. SymBio's pipeline includes drugs such as Treakisym, rigosertib, and brincidofovir, promoting new drug development in areas with high unmet medical needs. While the company has primarily focused its business operations in Japan and Asia, it now aims to expand globally to enhance its business value.